151 related articles for article (PubMed ID: 37269349)
21. Clozapine and desmethylclozapine: correlation with neutrophils and leucocytes counting in Mexican patients with schizophrenia.
Vaquero-Baez M; Díaz-Ruíz A; Tristán-López L; Aviña-Cervantes C; Torner C; Ramírez-Bermúdez J; Montes S; Ríos C
BMC Psychiatry; 2019 Oct; 19(1):295. PubMed ID: 31597566
[TBL] [Abstract][Full Text] [Related]
22. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine.
Tugnait M; Hawes EM; McKay G; Eichelbaum M; Midha KK
Chem Biol Interact; 1999 Apr; 118(2):171-89. PubMed ID: 10359460
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions?
Sangüesa E; Cirujeda C; Concha J; Padilla PP; García CB; Ribate MP
Chem Biol Interact; 2022 Sep; 364():110042. PubMed ID: 35853541
[TBL] [Abstract][Full Text] [Related]
25. Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia.
Costa-Dookhan KA; Rajji TK; Tran VN; Bowden S; Mueller DJ; Remington GJ; Agarwal SM; Hahn MK
Sci Rep; 2021 Jan; 11(1):2004. PubMed ID: 33479273
[TBL] [Abstract][Full Text] [Related]
26. Correlation between assessment of cytochrome P450 1A2 activity and enzyme activity scores, and their relation to clozapine exposure.
Alarcan H; Cannet P; Camus V; Fond G; Zendjidjian X; Guilhaumou R; Quaranta S
Br J Clin Pharmacol; 2023 May; 89(5):1665-1671. PubMed ID: 36507652
[TBL] [Abstract][Full Text] [Related]
27. Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking.
Dobrinas M; Cornuz J; Pedrido L; Eap CB
Pharmacogenet Genomics; 2012 Feb; 22(2):143-51. PubMed ID: 22246422
[TBL] [Abstract][Full Text] [Related]
28. Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients-a genome-wide association study adjusting for smoking habits.
Smith RL; O'Connell K; Athanasiu L; Djurovic S; Kringen MK; Andreassen OA; Molden E
Transl Psychiatry; 2020 Jun; 10(1):198. PubMed ID: 32555152
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies.
Molden E
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1211-1221. PubMed ID: 34461790
[TBL] [Abstract][Full Text] [Related]
30. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients.
Doude van Troostwijk LJ; Koopmans RP; Vermeulen HD; Guchelaar HJ
Eur J Pharm Sci; 2003 Dec; 20(4-5):451-7. PubMed ID: 14659489
[TBL] [Abstract][Full Text] [Related]
31. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine.
Lieberman JA; Phillips M; Gu H; Stroup S; Zhang P; Kong L; Ji Z; Koch G; Hamer RM
Neuropsychopharmacology; 2003 May; 28(5):995-1003. PubMed ID: 12700715
[TBL] [Abstract][Full Text] [Related]
32. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy.
Costa-Dookhan KA; Agarwal SM; Chintoh A; Tran VN; Stogios N; Ebdrup BH; Sockalingam S; Rajji TK; Remington GJ; Siskind D; Hahn MK
Expert Opin Drug Saf; 2020 Jan; 19(1):43-57. PubMed ID: 31770500
[No Abstract] [Full Text] [Related]
33. Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia.
Sarpal DK; Blazer A; Wilson JD; Calabro FJ; Foran W; Kahn CE; Luna B; Chengappa KNR
Schizophr Res; 2022 May; 243():170-177. PubMed ID: 35381515
[TBL] [Abstract][Full Text] [Related]
34. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.
Czerwensky F; Leucht S; Steimer W
Ther Drug Monit; 2015 Apr; 37(2):152-60. PubMed ID: 25090458
[TBL] [Abstract][Full Text] [Related]
35. The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients.
Kootstra-Ros JE; Smallegoor W; van der Weide J
Ann Clin Biochem; 2005 May; 42(Pt 3):216-9. PubMed ID: 15949157
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation.
Chetty M; d'Esposito F; Zhang WV; Glen J; Dore G; Stankovic Z; Edwards RJ; Ramzan I; Murray M
Br J Clin Pharmacol; 2009 Oct; 68(4):574-9. PubMed ID: 19843060
[TBL] [Abstract][Full Text] [Related]
37. Whole saliva and plasma levels of clozapine and desmethylclozapine.
Dumortier G; Lochu A; Zerrouk A; Van Nieuwenhuyse V; Colen de Melo P; Roche Rabreau D; Degrassat K
J Clin Pharm Ther; 1998 Feb; 23(1):35-40. PubMed ID: 9756110
[TBL] [Abstract][Full Text] [Related]
38. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia.
Schneider C; Corrigall R; Hayes D; Kyriakopoulos M; Frangou S
Eur Psychiatry; 2014 Jan; 29(1):1-10. PubMed ID: 24119631
[TBL] [Abstract][Full Text] [Related]
39. Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms.
Erickson-Ridout KK; Sun D; Lazarus P
Pharmacogenet Genomics; 2012 Aug; 22(8):561-76. PubMed ID: 22565219
[TBL] [Abstract][Full Text] [Related]
40. Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response.
Lee ST; Ryu S; Kim SR; Kim MJ; Kim S; Kim JW; Lee SY; Hong KS
J Clin Psychopharmacol; 2012 Aug; 32(4):441-8. PubMed ID: 22722500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
